Author | Richard W. Joseph, MD | OncLive

Author | Richard W. Joseph, MD

Articles

Dr. Joseph on Molecular Signatures in mRCC

September 04, 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on the Combination of Atezolizumab and Bevacizumab in mRCC

August 23, 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCC

August 05, 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).

Dr. Joseph on Selecting Frontline Therapy in mRCC

August 03, 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the process of selecting frontline therapy in metastatic renal cell carcinoma (mRCC).

x